Treating the Seeds of Cancer
athernal bio is developing the first immunotherapies for high-risk clonal haematopoiesis — addressing blood cancer precursor conditions with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.
MISSION
To design, develop and deliver the first targeted immunotherapies for high-risk blood cancer precursor conditions
UNMET NEED
Clonal haematopoiesis: a silent but widespread risk
Clonal haematopoiesis (CH) occurs when blood stem cells acquire mutations that give them a growth advantage. These altered stem cells expand over time, increasing the risk of blood cancers such as acute myeloid leukaemia (AML) and contributing to cardiovascular and other age-related diseases. Despite its prevalence and impact, there are currently no approved therapies for CH.

OUR APPROACH
A new therapeutic category for oncology
We are building immunotherapies that train the immune system to detect and eliminate CH-affected stem cells, addressing the earliest step in the development of blood cancers.
Frontline immunotherapy
Taking immunotherapy to the earliest stage of disease, before blood cancers emerge.

PIPELINE
Lead Programmes
athernal bio is developing targeted immunotherapies to treat clonal haematopoiesis before cancers become established.
EXPERTS
Meet our team
Clinicians, scientists and drug developers with deep experience in haematology, immunology and translational medicine.


Martin Olin
Board Member
Our Advisors


Prof. KJ Patel
Chief Scientist for CRUK, Director of the MRC Weatherall Institute of Molecular Medicine, University of Oxford


Dr. Juan Li
Department of Haematology, University of Cambridge


Christine Swenson, PhD
Regulatory Advisor
NEWS
The Latest at athernal



INVESTORS
Interested in supporting our mission?
Reach out to explore funding opportunities.









































